Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVERMECTIN vs ANTEPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
FDA-approved: Treatment of onchocerciasis (river blindness), strongyloidiasis, and intestinal infections caused by Strongyloides stercoralis.,FDA-approved: Scabies (topical formulation).,Off-label: Treatment of other parasitic infections including ascariasis, trichuriasis, enterobiasis, filariasis, loiasis, and cutaneous larva migrans.,Off-label: Treatment of severe, refractory, or crusted scabies (oral).,Off-label: Used in combination with albendazole for lymphatic filariasis.,Investigational: Used for scabies in institutional settings and for rosacea (topical).
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Terminal elimination half-life is approximately 18 hours (range 12-24 hours) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Ivermectin is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4. It is also a substrate of P-glycoprotein (P-gp).
Partially metabolized in the liver; some metabolites are excreted unchanged.
Primarily fecal (≥90% as unchanged drug and metabolites); renal excretion is minimal (<1% of dose). Biliary excretion contributes to fecal elimination.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Approximately 93% bound to plasma proteins, primarily albumin and possibly alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is 3.1-3.5 L/kg (large, indicating extensive tissue distribution including fat and skin).
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Oral bioavailability is approximately 60-80% (due to extensive first-pass metabolism). Topical bioavailability is negligible (<1% systemic absorption).
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
No dose adjustment required for any degree of renal impairment.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
Use with caution in severe hepatic impairment; specific Child-Pugh-based dosing not established.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
Weight-based: 150–200 mcg/kg orally once, same as adult; safety for children weighing less than 15 kg not established.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
No specific dose adjustment; monitor for adverse effects due to potential age-related organ dysfunction.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
No FDA black box warnings.
None.
Severe skin reactions (Mazzotti reaction) when treating onchocerciasis, including pruritus, urticaria, fever, arthralgias, syncope, and lymphadenitis.,Neurological toxicity in high doses or with compromised blood-brain barrier (e.g., due to meningitis, African trypanosomiasis, or Loa loa infection with high microfilarial loads).,Ocular reactions in onchocerciasis: exacerbation of eye lesions, including optic neuritis and chorioretinitis.,Potential for drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) or P-gp inhibitors (e.g., verapamil, cyclosporine), leading to increased ivermectin exposure.,Hypersensitivity reactions.,Use in pregnancy only if clearly needed (data limited).,Not recommended in children under 5 years of age or weighing less than 15 kg.
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Hypersensitivity to ivermectin or any component of the formulation.,Concurrent use with drugs that inhibit CYP3A4 or P-gp may require caution, but absolute contraindication is rare.,Loa loa infection with high microfilarial loads (risk of severe encephalopathy).
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
Ivermectin should be taken on an empty stomach with water. Administration with food, particularly high-fat meals, can significantly increase absorption (up to 2.5-fold), potentially increasing the risk of adverse effects. Therefore, avoid food for at least 2 hours before and 1 hour after dosing. Grapefruit juice may inhibit CYP3A4 and could theoretically increase ivermectin levels; caution is advised.
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in second/third trimester from observational studies.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Ivermectin is excreted into breast milk; M/P ratio unknown. Limited human data suggests low levels. Caution in infants weighing <15 kg due to potential CNS effects. Consider temporary cessation of breastfeeding during therapy.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
Pharmacokinetics in pregnancy not well studied. No recommended dose adjustments. Use standard weight-based dosing (150–200 mcg/kg) but avoid in first trimester unless essential.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
Ivermectin is a broad-spectrum antiparasitic agent that causes parasite death by increasing chloride ion conductance in invertebrate nerve and muscle cells. It is the drug of choice for onchocerciasis and strongyloidiasis, and is also used for scabies and head lice. For onchocerciasis, it is given as a single dose of 150 mcg/kg, repeated every 6-12 months. For strongyloidiasis, the recommended dose is 200 mcg/kg daily for 2 days. For crusted scabies, multiple doses (e.g., on days 1, 2, 8, 9) may be required. Note: Ivermectin does not kill adult Onchocerca worms but reduces microfilarial load. Severe adverse effects (Mazzotti reaction) can occur in onchocerciasis due to rapid microfilarial killing. Avoid in patients with Loa loa co-infection due to risk of encephalopathy. Ivermectin is not recommended for children under 15 kg or pregnant women unless benefits outweigh risks. Drug interactions: caution with CYP3A4 inhibitors or inducers; consider dose adjustment with strong inhibitors like ketoconazole.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
Take ivermectin exactly as prescribed, usually on an empty stomach with water.,For strongyloidiasis or scabies, you may need a second dose; complete the full course.,Do not take with food, especially high-fat meals, as they may increase absorption and risk of side effects.,Common side effects include dizziness, pruritus, and gastrointestinal upset.,Report any severe skin rash, swelling, or difficulty breathing immediately.,If being treated for onchocerciasis, you may experience a reaction (fever, itching, joint pain) due to dying parasites; this is usually mild and treatable.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or taking other medications.,Do not use ivermectin for COVID-19; it is not approved for viral infections.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
"Coadministration of ivermectin, a known inhibitor of cytochrome P450 3A4 (CYP3A4), with netupitant, a CYP3A4 substrate, can result in increased systemic exposure to netupitant. This may potentiate netupitant-related adverse effects, such as nausea, fatigue, and QT prolongation, particularly in patients with underlying hepatic impairment or those receiving other QT-prolonging agents."
"Ivermectin is a substrate of CYP3A4 and P-glycoprotein (P-gp), while imatinib is primarily metabolized by CYP3A4 and is also a substrate of P-gp. Concomitant administration of ivermectin may competitively inhibit CYP3A4 and P-gp, reducing the clearance of imatinib and increasing its systemic exposure. This can potentiate imatinib's adverse effects, including hepatotoxicity, fluid retention, and myelosuppression, particularly at high doses."
"Ivermectin is a moderate inhibitor of CYP3A4, the primary enzyme responsible for simeprevir metabolism. Concomitant administration significantly reduces simeprevir clearance, leading to elevated plasma concentrations. This increases the risk of simeprevir-related adverse effects, including hepatotoxicity, QT prolongation, and rash."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVERMECTIN vs ANTEPAR, answered by our medical review team.
IVERMECTIN is a Anthelmintic that works by Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.. ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVERMECTIN and ANTEPAR depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVERMECTIN is: 150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.. The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVERMECTIN and ANTEPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVERMECTIN is classified as Category A/B. FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in seco. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.